Videos

At the 2014 VEITHsymposium, Peter Schneider, MD, shared results from the European and US arms of the IN.PACT SFA trial, a multicenter randomized trial that evaluated safety and efficacy of the In.Pact Admiral drug-eluting balloon compared to...

At the 2014 VEITHsymposium, Thomas Zeller, MD, presented on the multicenter randomized controlled IN.PACT DEEP trial, which compared paclitaxel-coated balloons with uncoated balloons and which failed to show benefit for the drug-eluting...

Renal artery stenting is still controversial; however, it is still utilized in patients with resistant hypertension. Resistant lesions, as well as ostial renal stenosis, respond well to focal treatment with the AngioScore balloon as well as...

Jeffrey Lawson, MD, of Duke University, discusses engineering of an implantable blood vessel from donor vascular cells. The technology has received US Food and Drug Administration fast-track designation for approval, and clinical trials are...

Dr. Walker presents the March issue of Vascular Disease Management with a discussion of recent clinical results and FDA approvals of drug-eluting balloons. 

Although popliteal venous aneurysm is very rare, Dr. Walker notes that interventionalists should understand its etiology in the context of pulmonary embolism and deep venous thrombosis. 

In a patient who presented with STEMI and who had with hypotension and ventricular fibrillation that continued after recanalization of the infarct related vessel, the authors felt there was enough circumstantial evidence to warrant treatment...

With the final year of follow-up for the Zilver PTX study, results showed a clear benefit to drug-eluting stent vs standard balloon angioplasty. There was a significant difference with improvement that increased to 5 years.